Baseline characteristics of patients before left ventricular assist device implantation

ParametersRVAD with Protek Duo® cannula N = 8Open t-RVAD
N = 14
P
Age54.5 ± 14.156.3 ± 9.70.77
Sex (Male)4 (50)8 (57.1)0.76
BMI30.8 ± 6.533.0 ± 8.30.52
History of hypertension2 (25)10 (71.4)0.14
History of tobacco4 (50)6 (42.9)0.9
Ischemic cardiomyopathy5 (62.5)11 (78.6)0.62
EF before the implantation19 ± 616 ± 50.07
INTERMACS stage 15 (62.5)13 (92.9)0.12
Creatinine (mg/dL)1.54 ± 0.601.38 ± 0.580.58
Bilirubin (mg/dL)9 ± 13.811.0 ± 9.80.72
AST (unit/L)157 ± 16262 ± 360.61
Platelets (k/uL)186 ± 79140 ± 1070.27
Lactate (mmol/L)3 ± 2.74.8 ± 4.70.61
Albumin (g/dL)3.4 ± 0.402.96 ± 0.39< 0.001
MAP (mmHg)59 ± 1165 ± 70.20
CVP (mmHg)20 ± 515 ± 70.09
Mechanical ventilation the day before the LVAD implantation1 (12.5)7 (50)0.16
Pa02/Fi02 ratio before LVAD257 ± 133235 ± 1100.001
CRRT5 (62.5)9 (64.3)0.9
Short-term devices before LVAD
VA-ECMO5 (62.5)11 (78.6)0.47
Impella®1 (12.5)4 (28.60)
Both1 (12.5)1(7.1)
Type of LVAD
Heart Ware7 (87.5)6(42.9)0.07
HeartMate II1 (12.5)8 (57.1)
Oxygenator with RVAD [Y/N]8 (100)13 (92.9)0.9
Immediate RVAD implantation2 (25)12 (85.7)0.008
Delay implantation between LVAD and RVAD > 48 h5 (62.5)1 (7.1)0.01

RVAD: right ventricular assist device; BMI: body mass index; EF: ejection fraction; MAP: mean arterial pressure; CVP: central venous pressure; LVAD: left ventricular assist device: CRRT: continuous renal replacement therapy; VA-ECMO: veno-venous extracorporeal membrane oxygenation; AST: aspartate aminotransferase. Statistically significant differences are bolded and highlighted